Anakinra or rhIFNγ

Phase 2Small molecule

HHellenic Institute for the Study of Sepsis

Anakinra or rhIFNγ is one of 127 small molecule programs targeting Insulin Secretion. It is currently in Phase 2.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin SecretionActive, not recruiting

PneumoniaActive, not recruiting

SepsisActive, not recruiting

COVID-19Active, not recruiting

Insulin SecretionPhase 2

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

SepsisPhase 2

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Anakinra or rhIFNγ

HHellenic Institute for the Study of Sepsis

Phase 2

2 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2/3Recruiting

Safety and Efficacy

NCT05926505

Clinical

Trials by Indication[1]

COVID-192 trials

Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)

Completed·FFundacion Miguel Servet·Phase 2/3·NCT04443881·179 enrolled

A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study

Unknown status·KKarolinska University Hospital·Phase 2·NCT04412291·120 enrolled

Pneumonia1 trial

Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia

Completed·HHellenic Institute for the Study of Sepsis·Phase 2·NCT05785442·60 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

Recruiting·HHellenic Institute for the Study of Sepsis·Phase 2/3·NCT05926505·182 enrolled

Insulin Secretion1 trial

IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT04227769·18 enrolled

TBI1 trial

IL-1ra Dose-range Study for Moderate-to-severe TBI Patients

Unknown status·AAdel Helmy·Phase 2·NCT02997371·60 enrolled

1 more indication

Sepsis1 trial

Personalized Immunotherapy in Sepsis

Completed·HHellenic Institute for the Study of Sepsis·Phase 2·NCT04990232·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Anakinra or rhIFNγ. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anakinra or rhIFNγ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anakinra or rhIFNγ. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hellenic Institute for the Study of Sepsis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHellenic Institute for the Study of Sepsis

Anakinra or rhIFNγ

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

COVID-192 trials

Pneumonia1 trial

Safety and Efficacy1 trial

Insulin Secretion1 trial

TBI1 trial

Sepsis1 trial

References

Drug Info

Quick Facts

Related News